The estimated Net Worth of Elizabeth Barrett is at least $2.87 Million dollars as of 9 August 2023. Ms. Barrett owns over 2,000 units of Sage Therapeutics Inc stock worth over $22,470 and over the last 6 years she sold SAGE stock worth over $0. In addition, she makes $2,846,300 as Independent Director at Sage Therapeutics Inc.
Elizabeth has made over 2 trades of the Sage Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of SAGE stock worth $37,280 on 9 August 2023.
The largest trade she's ever made was buying 2,000 units of Sage Therapeutics Inc stock on 9 August 2023 worth over $37,280. On average, Elizabeth trades about 273 units every 8 days since 2019. As of 9 August 2023 she still owns at least 3,000 units of Sage Therapeutics Inc stock.
You can see the complete history of Ms. Barrett stock trades at the bottom of the page.
Elizabeth A. Barrett serves as Independent Director of the Company. Ms. Barrett currently serves as President and Chief Executive Officer of UroGen Pharma Ltd., a clinical-stage biopharmaceutical company focused on non-surgical uro-oncology treatments, a position she has held since January 2019. She previously served as Chief Executive Officer of Novartis Oncology, or Novartis, from February to December 2018. In that role, she oversaw more than 10,000 associates in 85 countries and sat on the Novartis executive committee. Prior to Novartis, she was Global President, oncology at Pfizer Inc., or Pfizer, from 2015 to 2017. From 2009 to 2015, she held a series of leadership positions at Pfizer, including President, Europe, Global Innovative Pharma, President, North America, and President, US Oncology business unit. Prior to Pfizer, from 2006 to 2009, Ms. Barrett was Vice President and General Manager of the Oncology business unit at Cephalon Inc. She also held senior roles at Johnson & Johnson from 1993 to 2006, working across their oncology, diagnostics, consumer products, and hospital and orthopedic markets sectors. Ms. Barrett received a B.S. from the University of Louisiana and an M.B.A. from Saint Joseph’s University.
As the Independent Director of Sage Therapeutics Inc, the total compensation of Elizabeth Barrett at Sage Therapeutics Inc is $2,846,300. There are 6 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
Elizabeth Barrett is 57, she's been the Independent Director of Sage Therapeutics Inc since 2019. There are 10 older and 6 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
Elizabeth's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen, and Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Sage Therapeutics Inc executives and other stock owners filed with the SEC include: